Fig. 3From: The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trialsTendency chart of OS rate (6-18 months, A) and PFS rate (3-15 months, B)Back to article page